UroGen Pharma Ltd. (URGN) compared with its closest peers (GYRE, ASRT, XNCR, CYTK, NRIX). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Gyre Therapeutics, Assertio, Xencor, Cytokinetics, Nurix Therapeutics, Karyopharm Therapeutics, Arcturus Therapeutics, MacroGenics, Eton Pharmaceuticals and Heron Therapeutics share UroGen Pharma's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $768.30M | 352.0 |
| Assertio Holdings, Inc. (ASRT) | $151.83M | -1.9 |
| Xencor, Inc. (XNCR) | $2.06B | -12.3 |
| Cytokinetics, Incorporated (CYTK) | $10.69B | -9.7 |
| Nurix Therapeutics, Inc. (NRIX) | $2.77B | -5.8 |
| Karyopharm Therapeutics Inc. (KPTI) | $44.57M | -0.4 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $382.29M | -2.5 |
| MacroGenics, Inc. (MGNX) | $257.35M | -1.4 |
| Eton Pharmaceuticals, Inc. (ETON) | $1.81B | 142.9 |
| Heron Therapeutics, Inc. (HRTX) | $64.55M | -10.8 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
URGN overview · URGN earnings · URGN financials · URGN KPIs · URGN documents · URGN ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.